GlassScriptPhysician profile
Miguel Angel Sutter
NPI 1619917903
$8,618.00
in general payments reported to CMS, 2019-2025
32 companies · $903 in 2025
The $903 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,689 · 2022: $1,311 · 2023: $925 · 2024: $790 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617 · Travel and Lodging: $1.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.92 |
| Travel and Lodging | $1.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,766.30 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $981.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $973.95 | 2021-2024 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $964.01 | 2021-2024 | Bexsero, Rotarix |
| Janssen Pharmaceuticals, INC | $740.25 | 2021-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $528.67 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $256.47 | 2021-2023 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.79 | 2021 | |
| Amgen INC. | $174.77 | 2021 | |
| Novo Nordisk INC | $161.45 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $148.92 | 2024 | Onivyde |
| Sanofi Pasteur INC. | $142.65 | 2023-2024 | |
| Medical Device Business Services, INC. | $140.53 | 2025 | Stratafix |
| Teva Pharmaceuticals USA, INC. | $134.29 | 2021-2023 | Austedo Xr |
| Esperion Therapeutics, INC. | $125.00 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $123.40 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2024 | |
| Gilead Sciences, INC. | $122.88 | 2025 | |
| Astellas Pharma US INC | $119.14 | 2021-2022 | |
| Ardelyx, INC. | $117.92 | 2025 | Ibsrela |
| Acadia Pharmaceuticals INC | $109.19 | 2025 | Daybue |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.71 | 2021 | |
| Alk-Abello, INC | $53.53 | 2025 | Neffy, Grastek, Ragwitek |
| Allergan, INC. | $46.60 | 2021 | |
| Merck Sharp & Dohme LLC | $39.83 | 2022 | |
| Cranial Technologies, INC | $31.33 | 2022-2025 | Doc Band |
| Pfizer INC. | $28.88 | 2023 | |
| Sanofi-Aventis U.S. LLC | $27.19 | 2025 | |
| Ethicon US, LLC | $24.74 | 2025 | Dermabond, Surgicel Nu-Knit |
| Ultragenyx Pharmaceutical INC. | $23.21 | 2021 | |
| Horizon Therapeutics Plc | $19.16 | 2021 | |
| Eisai INC. | $15.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.